124 related articles for article (PubMed ID: 7739337)
1. Virus infection and clotting factor concentrates.
Evans DI
Lancet; 1995 May; 345(8959):1247-8. PubMed ID: 7739337
[No Abstract] [Full Text] [Related]
2. Virus infection and clotting factor concentrates.
Rubinstein DB
Lancet; 1995 May; 345(8959):1248. PubMed ID: 7739339
[No Abstract] [Full Text] [Related]
3. Life-threatening human parvovirus B19 infection in immunocompetent haemophilia.
Yee TT; Lee CA; Pasi KJ
Lancet; 1995 Mar; 345(8952):794-5. PubMed ID: 7605434
[No Abstract] [Full Text] [Related]
4. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
5. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
[TBL] [Abstract][Full Text] [Related]
6. The case for wider use of recombinant factor VIII concentrates.
Hermans C; Brackmann HH; Schinco P; Auerswald G
Crit Rev Oncol Hematol; 2012 Jul; 83(1):11-20. PubMed ID: 21964312
[TBL] [Abstract][Full Text] [Related]
7. Viral safety and clotting factor concentrates.
Laurian Y; Lusher JM; Kessler CM
Thromb Haemost; 1994 Oct; 72(4):649. PubMed ID: 7878650
[No Abstract] [Full Text] [Related]
8. Antihemophilic factor isolated with monoclonal antibodies.
Gomperts ED
Ann Hematol; 1991 Sep; 63(3):142-4. PubMed ID: 1932289
[No Abstract] [Full Text] [Related]
9. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].
Sangre (Barc); 1994 Apr; 39(2):157-61. PubMed ID: 8059299
[No Abstract] [Full Text] [Related]
10. Hemophilia.
Aledort LM
N Engl J Med; 2001 Oct; 345(14):1066; author reply 1067. PubMed ID: 11586968
[No Abstract] [Full Text] [Related]
11. Parvovirus B19 and blood products.
Guillaume T
Lancet; 1994 Apr; 343(8905):1101. PubMed ID: 7909118
[No Abstract] [Full Text] [Related]
12. Therapy of factor VIII deficiency.
Gill JC
Semin Thromb Hemost; 1993; 19(1):1-12. PubMed ID: 8456319
[TBL] [Abstract][Full Text] [Related]
13. Virucidal treatment of clotting factor concentrates.
Mannucci PM; Colombo M
Lancet; 1988 Oct; 2(8614):782-5. PubMed ID: 2901620
[No Abstract] [Full Text] [Related]
14. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
15. On the way to virus-safe blood coagulation factor concentrates.
Schimpf K
Semin Thromb Hemost; 2002 Apr; 28 Suppl 1():15-24. PubMed ID: 12016574
[No Abstract] [Full Text] [Related]
16. Transfusion-transmitted disease.
Lee CA
Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic properties and safety of recombinant factor VIII and factor IX.
Zdziarska J; Chojnowski K; Klukowska A; Łetowska M; Mital A; Podolak-Dawidziak M; Windyga J; Zawilska K;
Pol Arch Med Wewn; 2009 Jun; 119(6):403-9. PubMed ID: 19694223
[TBL] [Abstract][Full Text] [Related]
18. GB virus C/hepatitis G virus infection in HIV infected patients with haemophilia despite treatment with virus inactivated clotting factor concentrates.
Woelfle J; Berg T; Bialek R; Keller KM; Effenberger W; Wagner N
Arch Dis Child; 1999 May; 80(5):429-32. PubMed ID: 10208947
[TBL] [Abstract][Full Text] [Related]
19. Parvovirus B19 antibodies in patients with haemophilia A.
Peerlinck K; Goubau P; Reybrouck R; Desmyter J; Vermylen J
Thromb Haemost; 1995 Mar; 73(3):555-6. PubMed ID: 7667846
[No Abstract] [Full Text] [Related]
20. Parvovirus B19 and blood products.
Prowse CV
Lancet; 1994 Apr; 343(8905):1101. PubMed ID: 7909119
[No Abstract] [Full Text] [Related]
[Next] [New Search]
